HCA062P specifically recognises the idiotypic determinants expressed by the rituximab humanised monoclonal antibody. Rituximab is a therapeutic reagent directed against the human CD20 cell surface antigen. HCA062P does not recognise other CD20 antibodies.
Product Form
A bivalent human recombinant Fab selected from the HuCAL® GOLD phage display library. Expressed in E. coli and purified using metal chelate affinity chromatography. This Fab fragment is dimerized via a helix-turn-helix motif. The antibody is tagged with a myc-tag (EQKLISEEDL) and a his-tag (HHHHHH) at the C-terminus of the antibody heavy chain and is conjugated to horseradish peroxidase.
Affinity
The monovalent intrinsic affinity of this antibody was measured as KD=10 nM by real time, label-free molecular interaction analysis on immobilized rituximab.
Application
This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visitwww.abdserotec.com/protocols.
Application Name
Yes
No
Not Determined
Suggested Dilution
ELISA
1/250 - 1/1000
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Store at +4oC. DO NOT FREEZE.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Shelf Life
12 months from date of despatch.
Licensed Use
For in vitro research purposes and for commercial applications for the provision of in vitro research testing services. Any re-sale or any other form of commercial application needs a written agreement with AbD Serotec.
Sold under license of U.S. Patents 6,300,064, 6,696,248, 6,708,484, 6,753,136, European patent 0,859,841 and corresponding patents.
Rituxan® is a registered trademark of Biogen Idec/Genentech in the USA.
MabThera ® is a registered trademark of Roche in Europe.
京公网安备11010802025653 版权所有：北京逸优科技有限公司
